Please login to the form below

Not currently logged in
Email:
Password:

Biotica and Pfizer end research partnership

Biotica reacquires full worldwide rights to rapamycin analogue programme after being in partnership with Pfizer since 2006

Biotica Technology has reacquired worldwide rights from Pfizer for its rapamycin analogue programme. The programme focuses developing treatments for neuro-inflammatory and other diseases.

Biotica made its original agreement to develop the programme with Wyeth Pharmaceuticals in early October 2006. Wyeth was then later acquired by Pfizer in October 2009. The deal included the worldwide rights to Biotica's most advance drug candidates at the time.

One of the key reasons for the alliance was due to Biotica's biosynthetic engineering technology. This enabled the creation of compounds, which through conventional synthetic chemistry at the time, were not readily available at the time.

Since then, Pfizer has explored the potential treatments researched as part of the programme in several diseases and has extensively profiled the candidate drugs in terms of multiple sclerosis and systemic lupus erythematosus.

Through the reacquisition of the programme, Biotica has control of compounds with a "strong data package". Biotica intends to continue development in this area, and carry out the extra research that is needed.

4th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics